[SCHEDULE 13G] SiNtx Technologies, Inc. SEC Filing

Rhea-AI Filing Summary

Form 4 overview: Director Cassandra Santos reported an insider transaction in Omnicom Group Inc. (OMC) dated 07/01/2025.

• Transaction type: Acquisition of 712.4 common shares. The shares were not bought on the open market but represent deferred compensation under the 2021 Incentive Award Plan, therefore recorded at a price of $0.
• Post-transaction holdings: Santos now directly holds 3,837.65 OMC shares, which include reinvested dividends credited on 04/09/2025.
• Ownership form: Direct.
• Signatory: The filing was executed by attorney-in-fact Eric J. Cleary on 07/03/2025.

No derivative securities were reported, and there were no dispositions. The filing does not disclose any monetary consideration, market purchase, or sale, limiting its potential market impact.

Insights

Securities Analyst

TL;DR: Small, compensation-related insider acquisition; informational only, limited market impact.

The 712-share acquisition stems from deferred equity, not an open-market buy, and brings the director’s stake to roughly 3.8 k shares. Given Omnicom’s ~200 m shares outstanding, the transaction is immaterial (<0.001%). There is no price signal or liquidity effect, so I classify the disclosure as neutral for investors.

Corporate Governance Expert

TL;DR: Routine director deferral under incentive plan; neutral governance signal.

Electing to defer equity aligns director compensation with shareholder interests, but the modest size means governance influence is negligible. No red flags—standard Rule 10b5-1 acknowledgement and timely filing. Impact on governance or share price is minimal.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sintx Technologies, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

829392703

(CUSIP Number)

07/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 829392703

1

Names of Reporting Persons

Sinaptic Holdings, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 216,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 216,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

216,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 216,450 shares of common stock ("Common Stock") and (ii) 325,000 unvested warrants to purchase shares of Common Stock (the "Warrants") that will vest, if at all, upon the achievement of certain performance goals over a four-year period starting July 1, 2025 and subject to a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 19.99% of the Issuer. Because the Warrants are unvested and subject to performance-based vesting goals, which have not yet been achieved, the shares of Common Stock underlying the Warrants are not deemed beneficially owned and have not been included in any of the amounts reported above.

SCHEDULE 13G

CUSIP No. 829392703

1

Names of Reporting Persons

Sinaptic Surgical, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 216,450.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 216,450.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

216,450.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 216,450 shares of Common Stock and (ii) 325,000 unvested Warrants to purchase shares of Common Stock that will vest, if at all, upon the achievement of certain performance goals over a four-year period starting July 1, 2025 and subject to a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 19.99% of the Issuer. Because the Warrants are unvested and subject to performance-based vesting goals, which have not yet been achieved, the shares of Common Stock underlying the Warrants are not deemed beneficially owned and have not been included in any of the amounts reported above.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sintx Technologies, Inc.
(b)	Address of issuer's principal executive offices: 1885 West 2100 South Salt Lake City, UT, 84119
Item 2.
(a)	Name of person filing: Sinaptic Holdings, LLC ("Holdings") and Sinaptic Surgical, LLC ("Surgical") (each, a "Reporting Person", and collectively, the "Reporting Persons") Surgical is the record holder of the shares reported herein. Holdings is the sole member and manager of Surgical. Consequently, it may be deemed the beneficial owner of shares held by Surgical and to have voting and investment control over such shares.
(b)	Address or principal business office or, if none, residence: The address of each Reporting Person is 591 Brookside Drive, Longmont, CO 80504
(c)	Citizenship: Each Reporting Person is organized in the State of Delaware.
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 829392703
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Holdings may be deemed to own 216,450 shares of Common Stock owned by Surgical. Surgical is also the record holder of 325,000 unvested Warrants that will vest, if at all, upon the achievement of certain performance goals over a four-year period starting July 1, 2025 and subject to a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 19.99% of the Issuer. Because the Warrants are unvested and subject to performance-based vesting goals, which have not yet been achieved, the shares of Common Stock underlying the Warrants are not deemed beneficially owned and have not been included in any of the amounts reported above.
(b)	Percent of class: Holdings: 7.9%* Surgical: 7.9%* *The percentage ownership is determined based on an aggregate 2,725,156 shares of Common Stock of the Issuer outstanding, which is the sum of (i) 2,508,706 shares of Common Stock outstanding as of May 13, 2025, as reported on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on May 15, 2025, and (ii) 216,450 shares of Common Stock owned by Surgical, which have been added to the total shares of Common Stock outstanding.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 216,450
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 216,450
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sinaptic Holdings, LLC

Signature:	/s/ Bryan Scheer
Name/Title:	Bryan Scheer / Chief Executive Officer
Date:	07/03/2025

Sinaptic Surgical, LLC

Signature:	/s/ Hugh Roberts
Name/Title:	Hugh Roberts / President
Date:	07/03/2025

Exhibit Information

99.1 Joint Filing Agreement, dated July 1, 2025, between Holdings and Surgical.

FAQ

How many Omnicom (OMC) shares did Director Cassandra Santos acquire?

712.4 common shares were credited to her deferred-compensation account on 07/01/2025.

What is Cassandra Santos’s total OMC shareholdings after the transaction?

She now directly owns 3,837.65 shares of Omnicom Group Inc.

Was the transaction an open-market purchase?

No. The shares were received at $0 under the Omnicom 2021 Incentive Award Plan (deferred compensation).

Did the Form 4 report any sales or derivative transactions?

No sales or derivative security transactions were disclosed in this filing.

When was the Form 4 signed and filed?

It was signed by attorney-in-fact Eric J. Cleary on 07/03/2025.